...
首页> 外文期刊>BMC Musculoskeletal Disorders >Perioperative multiple low-dose Dexamethasones improves postoperative clinical outcomes after Total knee arthroplasty
【24h】

Perioperative multiple low-dose Dexamethasones improves postoperative clinical outcomes after Total knee arthroplasty

机译:全膝关节置换术后围手术期多剂量小剂量地塞米松改善术后临床疗效

获取原文
   

获取外文期刊封面封底 >>

       

摘要

The purpose of this study was to investigate the efficacy and safety of multiple low-dose dexamethasones in primary total knee arthroplasty (TKA). One hundred fifty patients were equally randomized into 3 groups: Group A (n?=?50) received 2 doses of normal saline only; Group B (n?=?50) received with 1 dose of intravenous dexamethasone and 1 dose of normal saline; Group C (n?=?50) received with 2 doses of intravenous dexamethasone. The clinical outcomes and complications were assessed. The CRP and IL-6 were significantly lower in Group C and B than Group A at 24, 48, and 72?h postoperatively (P??0.001 for all). The intensity of postoperative nausea and vomiting (PONV) in Group C was lower than Group A at 24 (P??0.001, P?=?0.002), 48 (P?=?0.005, P?=?0.041) and 72?h (P?=?0.017, P?=?0.031) postoperatively and Group B at 24?h (P?=?0.027, P?=?0.019) postoperatively. Pain were significantly less in Group C than Group A at 24 (P??0.001), 48?h (P?=?0.037) postoperatively and Group B 24?h (P?=?0.030) postoperatively. Patients in Group C had better range of motion (ROM) and satisfaction than Group A (P??0.001, P?=?0.002) and B (P?=?0.001, P?=?0.043). No differences were found in complications. The administration of 10?mg dexamethasone 1?h before the surgery, and repeated at 6?h postoperatively can significantly reduce the level of postoperative CRP and IL-6 and the incidence of PONV, relieve pain, achieve an additional analgesic effect, and improve the early ROM compared with the other two groups in TKA. Therapeutic Level I. The Chinese Clinical Trial Registry ( ChiCTR1800017036 ). Registered on July 9, 2018.
机译:这项研究的目的是调查多种低剂量地塞米松在原发性全膝关节置换术(TKA)中的疗效和安全性。一百五十名患者平均分为三组:A组(n = 50)仅接受2剂生理盐水; B组(n = 50)接受1剂静脉地塞米松和1剂生理盐水。 C组(n≥50)接受2剂静脉地塞米松治疗。评估临床结果和并发症。术后24、48和72小时,C组和B组的CRP和IL-6显着低于A组(所有P <0.001)。 C组的术后恶心和呕吐(PONV)强度低于A组,分别为24(P <0.001,P = 0.002),48(P = 0.005,P = 0.041)和72。术后?h(P?=?0.017,P?=?0.031)和B组在术后24?h(P?=?0.027,P?=?0.019)。 C组的术后疼痛明显低于A组,分别为24(P 0.001),48?h(P <= 0.037)和B组24±h(P <= 0.030)。 C组患者的活动范围(ROM)和满意度高于A组(P 0.001,P <= 0.002)和B组(P <= 0.001,P = 0.043)。并发症无差异。术前1?h给予10?mg地塞米松,术后6?h重复使用可显着降低术后CRP和IL-6的水平以及PONV的发生率,减轻疼痛,达到额外的镇痛作用,并改善早期ROM与TKA中的其他两组相比。治疗级别I。中国临床试验注册中心(ChiCTR1800017036)。 2018年7月9日注册。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号